Coronary artery atherosclerosis is the leading cause of death in the United States. Restenosis following percutaneous transluminal balloon angioplasty (PTCA) remains the limiting factor in the use of this treatment for coronary artery disease. Restenosis occurs in 30% of patients within 6 months. The restenotic lesion is a fibroproliferative response with resulting smooth muscle cell migration, proliferation and extracellular matrix production. Despite a decade of research there is no effective strategy for preventing restenosis in man.